Orally Disintegrating Tablet Market Size, Share, Trends, Growth Outlook

Global Orally Disintegrating Tablet Market Size is Valued at $12.8 Billion in 2024 and is forecast to register a growth rate (CAGR) of 8.6% to reach $24.8 Billion by 2032.

The global Orally Disintegrating Tablet Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments -By Drug Class (Anti Psychotics, Anti Epileptics, CNS Stimulants, Anxiolytics, Anti Parkinsonian Drugs, Anti Hypertensives, NSAIDs, Anti-Allergy Drugs, Proton Pump Inhibitors, Others), By Indication (CNS Disease, GI Disease, CVS Disorders, Allergy, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies)

An Introduction to Orally Disintegrating Tablet Market

The Orally Disintegrating Tablet (ODT) market is growing as the demand for convenient and patient-friendly drug delivery forms increases. ODTs dissolve quickly in the mouth without the need for water, making them ideal for patients with swallowing difficulties, pediatric and geriatric populations, and those seeking rapid onset of action. The market is characterized by innovations in formulation technology, increasing adoption by pharmaceutical companies, and the growing acceptance of ODTs as a preferred drug delivery method for various therapeutic areas.

Orally Disintegrating Tablet Market Competitive Landscape

The market report analyses the leading companies in the industry including AstraZeneca, Bausch Health, Bayer AG, Dr. Reddy’s Laboratories Ltd, Eli Lily and Company, F Hoffman-La Roche Ltd, GlaxoSmithKline Plc, Johnson & Johnson Services Inc, Merck & Co Inc, Mylan N.V., Sun Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company Ltd, Teva Pharmaceutical Industries Ltd, and others.

Orally Disintegrating Tablet Market Dynamics

Orally Disintegrating Tablet Market Trend: Increasing Preference for Patient-Friendly Dosage Forms

A Market trend in the Orally Disintegrating Tablet (ODT) Market is the increasing preference for patient-friendly dosage forms. ODTs offer convenience, especially for pediatric, geriatric, and psychiatric patients who may have difficulty swallowing conventional tablets or capsules. This trend is driven by the demand for easy-to-administer medications that enhance patient compliance and medication adherence, leading to the expansion of the ODT market.

Orally Disintegrating Tablet Market Driver: Rising Incidence of Dysphagia and Geriatric Population

The rising incidence of dysphagia, a condition characterized by difficulty swallowing, along with the growing geriatric population, serves as a significant market driver for orally disintegrating tablets. Elderly individuals and patients with dysphagia often experience challenges in swallowing solid dosage forms, making ODTs an attractive alternative. As the elderly population grows and the prevalence of dysphagia increases, there is a corresponding increase in demand for ODTs, driving market growth.

Orally Disintegrating Tablet Market Opportunity: Expansion in Neurological and Psychiatric Therapies

One potential opportunity in the Orally Disintegrating Tablet Market lies in the expansion of ODTs for neurological and psychiatric therapies. ODTs offer advantages such as rapid onset of action, ease of administration, and improved patient compliance, making them well-suited for medications used to treat neurological and psychiatric disorders. With the rising prevalence of conditions such as Alzheimer's disease, schizophrenia, and bipolar disorder, there is a growing need for effective and convenient drug delivery systems, presenting an opportunity for manufacturers to develop and market ODT formulations tailored to these therapeutic areas.
Orally Disintegrating Tablet Market Share Analysis: Anti Psychotics generated the highest revenue in 2024The Anti Psychotics segment emerges as the largest in the Orally Disintegrating Tablet (ODT) Market, highlighting a significant demand for convenient and patient-friendly formulations for psychiatric conditions. Orally disintegrating tablets offer a practical alternative to traditional oral medications, particularly for patients who experience difficulty swallowing or require rapid drug absorption. With anti-psychotics being widely prescribed for various psychiatric disorders, including schizophrenia and bipolar disorder, the availability of ODT formulations facilitates improved medication adherence and treatment outcomes. Positioned within psychiatric clinics, hospitals, and outpatient settings, ODTs play a pivotal role in enhancing patient compliance and comfort while addressing the therapeutic needs of individuals with mental health conditions. As healthcare providers prioritize patient-centered care and personalized treatment approaches, the demand for ODT formulations in the anti-psychotics category continues to drive Market growth, shaping the landscape of oral drug delivery technologies.Orally Disintegrating Tablet Market Share Analysis: Central Nervous System (CNS) Disease is poised to register the fastest CAGR over the forecast period to 2030The Central Nervous System (CNS) Disease segment emerges as the fastest-growing segment in the Orally Disintegrating Tablet (ODT) Market, poised for substantial expansion by 2030. This trend reflects the increasing prevalence of CNS disorders, including neurological and psychiatric conditions such as Alzheimer's disease, Parkinson's disease, epilepsy, and mood disorders, driving the demand for innovative and patient-friendly drug delivery formulations. Orally disintegrating tablets offer a convenient and practical solution for administering medications to patients with CNS diseases, particularly those who may have difficulty swallowing or require rapid onset of action. Positioned within neurology clinics, psychiatric hospitals, and primary care settings, ODTs play a crucial role in improving medication adherence and therapeutic outcomes for individuals affected by CNS disorders. As advancements in neuroscience research and personalized medicine continue to reshape the treatment landscape for CNS diseases, the demand for ODT formulations tailored to address neurological and psychiatric indications is expected to surge, driving Market growth and fostering innovation in oral drug delivery technologies.Orally Disintegrating Tablet Market Share Analysis: Retail Pharmacies generated the highest revenue in 2024The Retail Pharmacies segment emerges as the largest in the Orally Disintegrating Tablet (ODT) Market, highlighting the significant accessibility and convenience offered by traditional brick-and-mortar pharmacy outlets. Retail pharmacies serve as primary points of access for patients to obtain prescription medications, including orally disintegrating tablets, conveniently located within community settings. With retail pharmacies positioned as trusted healthcare providers offering comprehensive medication management services, they play a pivotal role in dispensing ODT formulations prescribed for various medical conditions. As patients increasingly seek convenient and accessible healthcare solutions, retail pharmacies remain a preferred distribution channel for ODTs, providing personalized care and medication counseling to enhance patient compliance and therapeutic outcomes. With a growing emphasis on patient-centered care and pharmacy services, the demand for ODT formulations through retail pharmacies continues to drive Market growth, shaping the landscape of oral drug delivery technologies.

Orally Disintegrating Tablet Market Report Segmentation

By Drug Class
Anti Psychotics
Anti Epileptics
CNS Stimulants
Anxiolytics
Anti Parkinsonian Drugs
Anti Hypertensives
NSAIDs
Anti-Allergy Drugs
Proton Pump Inhibitors
Others
By Indication
CNS Disease
GI Disease
CVS Disorders
Allergy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies
Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Orally Disintegrating Tablet Market Companies Profiled in the Study

AstraZeneca
Bausch Health
Bayer AG
Dr. Reddy’s Laboratories Ltd
Eli Lily and Company
F Hoffman-La Roche Ltd
GlaxoSmithKline Plc
Johnson & Johnson Services Inc
Merck & Co Inc
Mylan N.V.
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Company Ltd
Teva Pharmaceutical Industries Ltd
*- List Not Exhaustive

TABLE OF CONTENTS

1 Introduction to 2024 Orally Disintegrating Tablet Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Orally Disintegrating Tablet Market Size Outlook, $ Million, 2021 to 2030
3.2 Orally Disintegrating Tablet Market Outlook by Type, $ Million, 2021 to 2030
3.3 Orally Disintegrating Tablet Market Outlook by Product, $ Million, 2021 to 2030
3.4 Orally Disintegrating Tablet Market Outlook by Application, $ Million, 2021 to 2030
3.5 Orally Disintegrating Tablet Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Orally Disintegrating Tablet Industry
4.2 Key Market Trends in Orally Disintegrating Tablet Industry
4.3 Potential Opportunities in Orally Disintegrating Tablet Industry
4.4 Key Challenges in Orally Disintegrating Tablet Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Orally Disintegrating Tablet Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Orally Disintegrating Tablet Market Outlook by Segments
7.1 Orally Disintegrating Tablet Market Outlook by Segments, $ Million, 2021- 2030
By Drug Class
Anti Psychotics
Anti Epileptics
CNS Stimulants
Anxiolytics
Anti Parkinsonian Drugs
Anti Hypertensives
NSAIDs
Anti-Allergy Drugs
Proton Pump Inhibitors
Others
By Indication
CNS Disease
GI Disease
CVS Disorders
Allergy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

8 North America Orally Disintegrating Tablet Market Analysis and Outlook To 2030
8.1 Introduction to North America Orally Disintegrating Tablet Markets in 2024
8.2 North America Orally Disintegrating Tablet Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Orally Disintegrating Tablet Market size Outlook by Segments, 2021-2030
By Drug Class
Anti Psychotics
Anti Epileptics
CNS Stimulants
Anxiolytics
Anti Parkinsonian Drugs
Anti Hypertensives
NSAIDs
Anti-Allergy Drugs
Proton Pump Inhibitors
Others
By Indication
CNS Disease
GI Disease
CVS Disorders
Allergy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

9 Europe Orally Disintegrating Tablet Market Analysis and Outlook To 2030
9.1 Introduction to Europe Orally Disintegrating Tablet Markets in 2024
9.2 Europe Orally Disintegrating Tablet Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Orally Disintegrating Tablet Market Size Outlook by Segments, 2021-2030
By Drug Class
Anti Psychotics
Anti Epileptics
CNS Stimulants
Anxiolytics
Anti Parkinsonian Drugs
Anti Hypertensives
NSAIDs
Anti-Allergy Drugs
Proton Pump Inhibitors
Others
By Indication
CNS Disease
GI Disease
CVS Disorders
Allergy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

10 Asia Pacific Orally Disintegrating Tablet Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Orally Disintegrating Tablet Markets in 2024
10.2 Asia Pacific Orally Disintegrating Tablet Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Orally Disintegrating Tablet Market size Outlook by Segments, 2021-2030
By Drug Class
Anti Psychotics
Anti Epileptics
CNS Stimulants
Anxiolytics
Anti Parkinsonian Drugs
Anti Hypertensives
NSAIDs
Anti-Allergy Drugs
Proton Pump Inhibitors
Others
By Indication
CNS Disease
GI Disease
CVS Disorders
Allergy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

11 South America Orally Disintegrating Tablet Market Analysis and Outlook To 2030
11.1 Introduction to South America Orally Disintegrating Tablet Markets in 2024
11.2 South America Orally Disintegrating Tablet Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Orally Disintegrating Tablet Market size Outlook by Segments, 2021-2030
By Drug Class
Anti Psychotics
Anti Epileptics
CNS Stimulants
Anxiolytics
Anti Parkinsonian Drugs
Anti Hypertensives
NSAIDs
Anti-Allergy Drugs
Proton Pump Inhibitors
Others
By Indication
CNS Disease
GI Disease
CVS Disorders
Allergy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

12 Middle East and Africa Orally Disintegrating Tablet Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Orally Disintegrating Tablet Markets in 2024
12.2 Middle East and Africa Orally Disintegrating Tablet Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Orally Disintegrating Tablet Market size Outlook by Segments, 2021-2030
By Drug Class
Anti Psychotics
Anti Epileptics
CNS Stimulants
Anxiolytics
Anti Parkinsonian Drugs
Anti Hypertensives
NSAIDs
Anti-Allergy Drugs
Proton Pump Inhibitors
Others
By Indication
CNS Disease
GI Disease
CVS Disorders
Allergy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
AstraZeneca
Bausch Health
Bayer AG
Dr. Reddy’s Laboratories Ltd
Eli Lily and Company
F Hoffman-La Roche Ltd
GlaxoSmithKline Plc
Johnson & Johnson Services Inc
Merck & Co Inc
Mylan N.V.
Sun Pharmaceutical Industries Ltd
Takeda Pharmaceutical Company Ltd
Teva Pharmaceutical Industries Ltd

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Drug Class
Anti Psychotics
Anti Epileptics
CNS Stimulants
Anxiolytics
Anti Parkinsonian Drugs
Anti Hypertensives
NSAIDs
Anti-Allergy Drugs
Proton Pump Inhibitors
Others
By Indication
CNS Disease
GI Disease
CVS Disorders
Allergy
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Drug Stores
Online Pharmacies

Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)